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The first successful recordings of electrical activity from the human brain using scalp 
EEG were performed nearly a century ago (Berger, 1929). Its clinical relevance, 
particularly for epilepsy, was realized and established within a few years. Since then, 
scalp EEG has found many applications in neurological and neuropsychiatric 
disorders (Schomer et al., 2018). However, the limitations of EEG were already 
acknowledged in these early years, notably by one of its pioneers, Edgar Adrian, who 
wrote “With present methods the skull and the scalp are too much in the way, and we 
need some new physical method to read through them” (Adrian, 1944). It took another 
40 years before such a technique, Magnetoencephalography (MEG), was developed 
(Cohen, 1968, 1972). MEG records the extracranial magnetic fields that are induced, 
unperturbed by the skull and scalp, by the electrical activity in the brain. Further 
developments in analysis approaches and hardware, particularly the availability of 
whole-head systems and the increases in computing power that are needed to display 
and analyze these spatially- and temporally-rich signals, have ensured that MEG is 
now a mature technique. It has an important clinical role in epilepsy, where it is used 
for diagnosis and for the presurgical evaluation of patients with refractory epilepsy 
who are candidates for neurosurgical treatment. During this presurgical workup, MEG 
is used to generate an hypothesis about the epileptogenic zone, i.e., the minimum area 
that needs to be resected in order to achieve seizure freedom (Luders et al., 2006), and 
to establish eloquent cortex that needs to be spared because of its involvement in 
sensation, motor function, or language. 
 A question that can justifiably be asked is: why is it that despite the obvious 
advantages of MEG and its close relationship with EEG, that there are not many more 
established clinical applications of MEG? In particular: why is MEG not used more 
widely in epilepsy or neurodegenerative and neuropsychiatric disorders (Stam, 2010)? 
One of the reasons could be historical: the medical community was involved 
in EEG from the outset; Hans Berger was a psychiatrist, and Edgar Adrian an 
electrophysiologist. In contrast, the MEG community has for a long time been 
dominated by physicists and engineers, and later on also by neuroscientists, for whom 
identifying opportunities for, and development of, clinical applications might not have 
been top priority.  
Another reason could be that due to the richness and complexity of MEG data, 
there are many factors that should be taken into account when recording and 
analyzing these data. As a consequence, there are few generally accepted protocols for 
MEG. The IFCN-endorsed practical guidelines for clinical magnetoencephalography 
presented in this issue of Clinical Neurophysiology, Hari et al. (2018), attempt to 
address this latter issue. The guidelines are written by an international group of 
prominent experts who bring with them many years of experience in the development 
of MEG and its application in both neuroscience and clinical care. As one would 
expect from such a group, the guidelines do contain, besides a comprehensive 
introduction to MEG, many useful practical tips that help in obtaining high quality 
MEG data, in performing thorough analysis, and writing clear and informative 
reports. These guidelines could therefore aid the establishment of standardized clinical 
protocols. Although we expect that these guidelines will be broadly supported, it 
should be noted that the authors represent a minority of the clinical MEG users, and 
that the guidelines are therefore potentially incomplete and biased by the experiences 
and expertise of its authors. Moreover, although these are the first IFCN-endorsed 
clinical MEG guidelines, several clinical and general MEG guidelines already exist: 
The American Clinical Magnetoencephalography Society has published guidelines for 
the recording and analysis of spontaneous activity (Bagic et al., 2011b), presurgical 
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mapping (Burgess et al., 2011), reporting (Bagic et al., 2011c), and qualification of 
MEG/EEG personnel (Bagic et al., 2011a). The Japanese clinical MEG community 
has published guidelines regarding recording, analysis and documentation (Hashimoto 
et al., 2005), and many practical tips can also be found in Gross et al. (2013). 
Similarly, there is a large overlap with guidelines for clinical use of EEG and evoked 
potentials as endorsed by the IFCN0F0F
1
 and ACNS1F1F
2
. Integration of information between 
these guidelines is missing: it will be difficult for novice users of clinical MEG to 
determine which guidelines should be adopted, which represent conventional (i.e., 
historical) preferences, and which were based on a consensus approach. Hence, 
although these new guidelines would provide novice clinical users a quick 
introduction to MEG, as well as many practical tips, for more detailed guidelines 
regarding specific applications one would be well advised to consult these alternatives 
as well.  
Another issue that has been holding back the clinical application of MEG is 
the absence (in comparison with EEG) of analysis and reporting software that 
combines ease of use in a clinical environment with access to sophisticated analysis 
routines. Many MEG laboratories develop their own software tools or use open source 
packages (Baillet et al., 2011). These packages have many advantages, such as access 
to sophisticated analysis routines and flexibility to add new ones. However, clinical 
use also requires that the software fulfils the regulatory requirements (FDA 
approval/CE marking), that it enables easy access to data by clinicians, and that a 
clinical report can be generated quickly. These latter aspects often mean that the data 
should be moved from a Unix environment, in which data are acquired, to a Microsoft 
Windows environment, that the software contains a database through which the data 
are accessible, and that data can be processed quickly and (semi-)automatically. The 
former aspect means that developing such software is prohibitively expensive in a 
relatively small marketplace. This has led to a chicken-and-egg situation, where it is 
difficult to establish the clinical utility of MEG due to the absence of clinical 
software, and where clinical software is not developed because there are not enough 
clinical applications that warrant the investment. One strategy to break this deadlock 
is to take existing clinical EEG applications and convert them to MEG. By doing so, 
patients benefit from a more comfortable and faster recording, and researchers benefit 
from the build-up of large datasets that can be utilized for more advanced analyses 
than what would be possible with EEG. Analysis of oscillatory activity and evoked 
activity with regards to brain anatomy, functional interactions and topology of 
functional networks, all benefit from MEG’s simpler forward solutions, absence of the 
choice of reference, and increased number of sensors in comparison to clinical EEG. 
Importantly, by building up databases of sizes that are rarely achieved in research-
based projects, one can start to utilize ‘big data’ approaches in order to discover 
biomarkers for diagnosis and prognosis, which may lead to novel clinical applications 
of MEG. For example, Bosl et al. (2018) have applied machine learning methods to 
resting-state EEG data and can now predict autism in infants as young as 3 months old 
– a demonstration with obvious implications for early-intervention treatment 
strategies.  
Initially, one could start with conversion of relatively straightforward EEG 
protocols, such that analysis can be carried out using software that has not yet been 
optimized for clinical use (at the expense of an extra time-investment by MEG 
technicians and clinicians for analysis and interpretation). As an example, our group 
                                                          
1
 http://www.ifcn.info  
2
 https://www.acns.org/practice/guidelines 
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has taken a clinical EEG protocol for diagnosis of patients in the memory clinic 
(Gouw et al., 2016) and converted that to MEG. That is, the EEG recording/reporting 
protocols and outcome measures are used, but for MEG the analysis is performed on 
source-reconstructed data, alongside the sensor-level analysis that would have been 
done with EEG. By doing so, a cohort consisting of more than 240 patients has been 
built in 3 years’ time. One envisages that this strategy could readily be adopted to 
some of the clinical applications that the guidelines describe as being on the horizon: 
mild traumatic brain injury, stroke, chronic pain, hepatic encephalopathy, psychiatric 
disorders, brain maturation, autism, and Parkinson’s disease (e.g. Klassen et al., 2011, 
Olde Dubbelink et al., 2014). Conversion to common clinical practice may be further 
accelerated by the sharing of large datasets for healthy controls that were recorded in 
accordance with the guidelines (Niso et al., 2016), so that age- and gender-matched 
population means and standard deviations can be derived against which the clinical 
data can be assessed. 
More advanced protocols could be tackled when new technologies become 
available that address potential stumbling blocks for wider uptake of MEG as a 
clinical technique, such as installation and running costs, as well as access to some 
patient populations (e.g. neonates, comatose patients, and patients on intensive and 
medium care). The guidelines describe a few exciting new techniques that include 
high-temperature SQUIDS, hybrid quantum interference devices, and optically 
pumped magnetometers.   
In conclusion, these IFCN-endorsed general guidelines for clinical MEG will 
be a valuable resource for novice clinical users of MEG and represents another 
important step to support and encourage expert clinical groups to transfer their skills 
in clinical EEG to clinical MEG. Hopefully, new guidelines for specific clinical MEG 
applications will be needed soon.   
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